| Literature DB >> 33395956 |
Anders Lillevik Thorsen1, Stella J de Wit2, Pernille Hagland3, Olga Therese Ousdal4, Bjarne Hansen5, Kristen Hagen6, Gerd Kvale3, Odile A van den Heuvel7.
Abstract
Response inhibition has previously been suggested as an endophenotype for obsessive-compulsive disorder (OCD), evidenced by studies showing worse task performance, and altered task-related activation and connectivity. However, it's unclear if these measures change following treatment. In this study, 31 OCD patients and 28 healthy controls performed a stop signal task during 3 T functional magnetic resonance imaging before treatment, while 24 OCD patients and 17 healthy controls were rescanned one week and three months after concentrated exposure and response prevention over four consecutive days using Bergen 4-Day Format. To study changes over time we performed a longitudinal analysis on stop signal reaction time and task-related activation and amygdala connectivity during successful and failed inhibition. Results showed that there was no group difference in task performance. Before treatment, OCD patients compared to controls showed less inhibition-related activation in the right inferior frontal gyrus, and increased functional connectivity between the right amygdala and the right inferior frontal gyrus and pre-supplementary motor area. During error-processing, OCD patients versus controls showed less activation in the pre-SMA before treatment. These group differences did not change after treatment. Pre-treatment task performance, brain activation, and connectivity were unrelated to the degree of symptom improvement after treatment. In conclusion, inferior frontal gyrus hypoactivation and increased fronto-limbic connectivity are likely trait markers of OCD that remain after effective exposure therapy.Entities:
Keywords: Connectivity; Hypoactivation; Inferior frontal gyrus; OCD; Response inhibition; Treatment
Mesh:
Year: 2020 PMID: 33395956 PMCID: PMC7606869 DOI: 10.1016/j.nicl.2020.102460
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Baseline demographic and clinical characteristics.
| OCD (n = 31) | HC (n = 26) | |||
|---|---|---|---|---|
| M (SD) | M (SD) | t | p | |
| Age | 30.19 (9.21) | 31 (10.73) | 0.31 | 0.76 |
| Education (years) | 14.58 (2.41) | 14.43 (2.30) | 0.25 | 0.81 |
| n (%) | n (%) | χ2 | P | |
| Female | 19 (61) | 18 (64) | 0.06 | 1 |
| Handedness (right) | 29 (94) | 26 (93) | 0.01 | 1 |
| On medication | 7 (23) | – | – | – |
| SSRI | 6 (19) | – | – | – |
| Methylphenidate | 1 (3) | – | – | – |
| Childhood onset of OCD | 14 (45) | – | – | – |
| Major Depressive Disorder | 9 (29) | – | – | – |
| Generalized Anxiety Disorder | 9 (29) | – | – | – |
| Social Anxiety Disorder | 7 (23) | – | – | – |
| Specific Phobia | 4 (13) | – | – | – |
| Panic disorder with/without agoraphobia | 3 (10) | – | – | – |
| Hypochondriasis | 3 (10) | – | – | – |
| Dysthymia | 2 (7) | – | – | – |
| Post-Traumatic Stress Disorder | 1 (3) | – | – | – |
| Attention Deficit Hyperactivity Disorder | 1 (3) | – | – | – |
| Somatization disorder | 1 (3) | – | – | – |
| Pain disorder | 1 (3) | – | – | – |
Abbreviations: HC, healthy controls; OCD, obsessive–compulsive disorder; SSRI, selective serotonin reuptake inhibitors.
Regions of interest for successful and failed inhibition (defined as 10 mm spheres around peak).
| Region | Hemisphere | MNI coordinates (X, Y, Z) |
|---|---|---|
| Anterior insula/IFG | L | –33, 23, 5 |
| Anterior insula/IFG | R | 35, 23, −11 |
| Pre-SMA | L | −6, 11, 50 |
| Pre-SMA | R | 3, 20, 53 |
| Operculum | L | −42, 5, 29 |
| Operculum | R | 44, 10, 29 |
| Inferior parietal cortex | L | −55, −46, 35 |
| Inferior parietal cortex | R | 55, −46, 21 |
| Posterior cingulate cortex | Midline | 2, −24, 32 |
| Dorsal ACC | Midline | 0, 21, 34 |
| Pre-SMA | Midline | 0, 11, 62 |
Abbreviations: ACC, anterior cingulate cortex; IFG, inferior frontal gyrus; MNI, Montreal Neurological Institute; pre-SMA, pre-supplementary motor area.
Symptom scores over time in OCD patients (n = 24) and healthy controls (n = 17).
| Variable | Group | Before treatmentM (SD) | After one weekM (SD) | After three monthsM (SD) |
|---|---|---|---|---|
| Y-BOCS | OCD | 26.83 (4.26) | 10.33 (5.58) | 10.33 (6.37) |
| GAD-7 | OCD | 12.46 (5.33) | 8.41 (4.23) | 7.10 (4.52) |
| HC | 2.16 (2.63) | 1.89 (2.05) | 2.00 (2.17) | |
| PHQ-9 | OCD | 11.08 (5.83) | 8.73 (6.10) | 8.32 (5.49) |
| HC | 2.53 (1.71) | 2.32 (1.83) | 2.11 (1.53) |
Abbreviations: GAD-7, Generalized Anxiety Disorder 7; HC, healthy controls; OCD, obsessive–compulsive disorder; PHQ-9, Patient Health Questionnaire 9; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
Task performance inhibition between OCD (n = 24) and HC (n = 19) over time.
| Before treatmentM (SD) | After one weekM (SD) | After three monthsM (SD) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCD | HC | t | p | OCD | HC | t | p | OCD | HC | t | p | |||
| SSRT (ms) | 203.94 (28.18) | 203.68 (47.09) | 0.02 | 0.98 | 193.4 (35.80) | 201.65 (55.39) | 0.08 | 0.56 | 196.87 (33.81) | 213.72 (48.19) | 1.35 | 0.19 | ||
| Mean go-trial RT (ms) | 506.67 (103.38) | 549.15 (141.47) | 1.14 | 0.26 | 504.08 (120.81) | 563.67 (187.45) | 1.26 | 0.21 | 496.46 (101.87) | 554.5 (174.87) | 1.36 | 0.18 | ||
| Errors on go-trials (%) | 0.02 (0.01) | 0.01 (0.02) | 0.37 | 0.71 | 0.02 (0.02) | 0.02 (0.02) | 0.37 | 0.52 | 0.02 (0.03) | 0.03 (0.04) | 1.46 | 0.15 | ||
Abbreviations: HC, healthy controls; OCD, obsessive–compulsive disorder; RT, response time.
Group differences in activation during inhibition between OCD (n = 31) and HC (n = 26) before treatment.
| IFG | R | 47 | 3 | 42 | 20 | −16 | 3.76 | 0.023 | 0.001 | HC > OCD |
Abbreviations: HC, healthy controls; IFG, inferior frontal gyrus; OCD, obsessive–compulsive disorder; R, right.
Fig. 1Right IFG activation and connectivity between the right amygdala and right pre-SMA during successful inhibition in OCD patients (n = 24) and healthy controls (n = 17). Legend Fig. 1: Panel A depicts the voxels in the right inferior frontal gyrus (IFG) where OCD patients showed less activation than healthy controls during successful inhibition compared to successful go-trials. B shows activation parameter estimates in the right IFG during successful inhibition compared to successful go-trials for each group and timepoint, as well as individual data points. Panel C depicts the voxels in the pre-SMA where OCD patients and healthy controls showed significant differences in right amygdala connectivity during successful inhibition versus successful go-trials D shows condition-specific connectivity estimates between the right amygdala and right pre-SMA during successful stop and go-trials. Healthy controls show a non-significant tendency towards stronger connectivity between the right pre-SMA and right amygdala during successful go-trials, while OCD patients show significantly stronger connectivity between the two regions during successful inhibition before treatment and three months after treatment. * indicates a significant group difference at p < .05 based on parameter estimates extracted using 6 mm spheres, with error bars representing one standard error.
Group differences in amygdala connectivity during inhibition between OCD (n = 31) and HC (n = 26) before treatment.
| R amygdala | Pre-SMA | Midline | 8 | 14 | 0 | 26 | 59 | 5.21 | 0.001 | <0.001 | OCD > HC |
| R amygdala | IFG | R | 47 | 10 | 33 | 26 | −16 | 3.46 | 0.071 | <0.001 | OCD > HC |
Abbreviations: HC, healthy controls; IFG, inferior frontal gyrus; OCD, obsessive–compulsive disorder; Pre-SMA, pre-supplementary motor area; R, right.
Effect of group for amygdala connectivity during inhibition between OCD (n = 24) and HC (n = 17) over time.
| R amygdala | Pre-SMA | R | 8 | 2 | 3 | 23 | 56 | 17.73 | 0.042 | <0.001 | OCD > HC |
Abbreviations: HC, healthy controls; OCD, obsessive–compulsive disorder; Pre-SMA, pre-supplementary motor area; R, right.
Fig. 2Task-related connectivity between the right amygdala and right pre-SMA during successful inhibition in OCD patients (n = 24) and healthy controls (n = 17). Psychophysiological interaction for connectivity between the right amygdala and right pre-SMA during successful stop and go-trials. Healthy controls show no significant changes in connectivity between the successful inhibition and successful go-trials, while OCD patients show significantly stronger more positive connectivity during successful inhibition than successful go-trials before treatment and three months after treatment. * indicates a significant group difference at p < .05 based on parameter estimates extracted using 6 mm spheres, with error bars representing one standard error.